Related Experiment Video
Updated: Jun 29, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells
Seiichi Okabe1, Mitsuru Moriyama1, Akihiko Gotoh1
1Department of Hematology, Tokyo Medical University, Tokyo, Japan.
Background:
Asciminib is approved for treating patients with chronic-phase chronic myeloid leukemia who were previously treated with two or more tyrosine kinase inhibitors or those with T315I mutation. However, the mechanisms underlying asciminib resistance remain unclear.
Methods:
In this study, we established a new asciminib-resistant cell line. We examined BCR::ABL1 gene mutation analysis and the effects of conventional chronic myelogenous leukemia inhibitors.
Results:
Direct sequencing revealed Y139D and T315I mutations in asciminib-resistant cells. Ponatinib and omacetaxine were effective against asciminib-resistant cells.
Conclusions:
Y139D and T315I mutations are extremely resistant to asciminib. Ponatinib and omacetaxine show potential for treating asciminib-resistant chronic myeloid leukemia.
Insights
New research identifies asciminib resistance mechanisms in chronic myeloid leukemia (CML). Y139D and T315I mutations confer resistance, but ponatinib and omacetaxine show promise for treating resistant CML.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Asciminib is approved for chronic myeloid leukemia (CML) patients with prior tyrosine kinase inhibitor (TKI) exposure or T315I mutation.
- Mechanisms of asciminib resistance in CML are not fully understood.
- Understanding resistance is crucial for optimizing CML treatment strategies.
Purpose of the Study:
- To investigate the molecular mechanisms of asciminib resistance in chronic myeloid leukemia.
- To establish and characterize an asciminib-resistant CML cell line.
- To evaluate potential therapeutic strategies against asciminib-resistant CML.
Main Methods:
- Established a novel asciminib-resistant chronic myeloid leukemia cell line.
- Performed BCR::ABL1 gene mutation analysis on resistant cells.
- Assessed the efficacy of conventional CML inhibitors against resistant cells.
Main Results:
- Identified Y139D and T315I mutations in asciminib-resistant CML cells via direct sequencing.
- These mutations demonstrated extreme resistance to asciminib.
- Ponatinib and omacetaxine exhibited significant efficacy against asciminib-resistant cells.
Conclusions:
- Y139D and T315I mutations are key drivers of asciminib resistance in CML.
- Ponatinib and omacetaxine represent potential therapeutic options for patients with asciminib-resistant CML.
- Further research is warranted to explore combination therapies for resistant CML.
